$Editas Medicine (EDIT.US)$ NEWS Editas Medicine Preclinical...
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, showing a decrease in intraocular pressure in a model of myocilin-associated primary open-angle glaucoma.
The development of an optimized LNP specifically for in vivo gene editing and the identification of modifications to improve in vivo editing efficiency are promising advancements showcased in the preclinical data.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, showing a decrease in intraocular pressure in a model of myocilin-associated primary open-angle glaucoma.
The development of an optimized LNP specifically for in vivo gene editing and the identification of modifications to improve in vivo editing efficiency are promising advancements showcased in the preclinical data.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
627Followers
74Following
4024Visitors
Follow